What Is Keytruda and Why Is Everyone Talking About It in India’s Cancer Fight?v

Keytruda has become one of the most talked-about cancer medicines in India as discussions around advanced immunotherapy, treatment access, and affordability continue to grow.

Keytruda, an advanced immunotherapy drug, is at the center of India’s cancer treatment and affordability debate.

Known generically as pembrolizumab, Keytruda is a breakthrough immunotherapy drug that helps the body’s immune system identify and attack cancer cells. It is widely used across the world for treating several cancers, including lung cancer, cervical cancer, melanoma, head and neck cancers, and kidney cancer.

What Exactly Is Keytruda?

Keytruda is an immune checkpoint inhibitor.

Unlike chemotherapy, which directly attacks fast-growing cells, Keytruda works by helping the body’s own immune system fight cancer.

Its main target is the PD-1 protein found on T-cells (immune cells).

Normally, some cancer cells use a protein called PD-L1 to “switch off” these T-cells, allowing the tumour to hide from the immune system.

Keytruda blocks this PD-1/PD-L1 interaction, effectively reactivating the immune response against cancer cells.

This is why it is often described as a game-changing immunotherapy drug.

Why Is Everyone Talking About It in India?

The drug is currently in focus for two major reasons:

1) Its Life-Saving Potential

Doctors across India are increasingly using immunotherapy in cancer care.

Keytruda has shown strong outcomes in:

• advanced lung cancer

• melanoma

• cervical cancer

• oral cancer

• renal cell carcinoma

• triple-negative breast cancer

For many patients, it can improve survival rates and reduce recurrence risk.

2) Its Extremely High Cost

The bigger conversation in India is around affordability.

Recent studies highlighted that a six-month course of Keytruda can cost nearly eight years of an average Indian’s income, making it one of the most expensive cancer treatments available.

Reports estimate treatment costs can run into lakhs per month, which places immense pressure on families.

This has triggered discussions around:

• cheaper biosimilars

• government support

• import duty relief

• insurance coverage

  
  

Why It Matters for India’s Cancer Fight

India reports around 15–16 lakh new cancer cases every year, making access to advanced therapies a major healthcare issue.

Keytruda represents the future of oncology treatment, but its price remains a serious challenge.

This is why experts are now talking about:

• local manufacturing

• affordable alternatives

• biosimilar development

• policy support for cancer drugs

  
  

Final Takeaway

Keytruda is being talked about because it represents both hope and challenge in India’s cancer fight.

It offers cutting-edge treatment outcomes, but affordability remains the key issue.

The debate now is not just about the medicine itself, but whether advanced cancer care can become accessible to ordinary Indian families.